Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries.

Liver Cancer · 2025 · PMC12005689 · PMID 40255875

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Compared with the use of second-line treatment of 33% at the time when the REFLECT trial was conducted, our study showed a trend of increasing use of second-line treatment [ 17 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.